Formulation of tablets containing an ‘in-process’ amorphized active pharmaceutical ingredient

By Jójárt-Laczkovich Orsolya   Szabó-Révész Piroska  

Drug Development and Industrial Pharmacy, Vol. 37, Iss. 11, 2011-11 ,pp. : 1272-1281

Informa Healthcare

Access to resources Recommend Favorite

17 α-Hydroxyprogesterone Caproate (Makena™): In the Prevention of Preterm Birth

By Deeks Emma D.  

Pediatric Drugs, Vol. 13, Iss. 5, 2011-10 ,pp. : 337-345

Adis International

Access to resources Recommend Favorite

Chemical interactions between an active pharmaceutical ingredient and its counterion in a tromethamine salt under forced degradation conditions

By Loeser Eric   Sutton Paul   Skorodinsky Ada   Lin Melissa   Yowell Guy  

Drug Development and Industrial Pharmacy, Vol. 38, Iss. 3, 2012-03 ,pp. : 357-364

Informa Healthcare

Access to resources Recommend Favorite

Use of Near-Infrared for Quantitative Measurement of Viscosity and Concentration of Active Ingredient in Pharmaceutical Gel

By Donoso M.   Ghaly E.S.  

Pharmaceutical Development and Technology, Vol. 11, Iss. 3, 2006-09 ,pp. : 389-397

Informa Healthcare

Access to resources Recommend Favorite

17α -Hydroxyprogesterone caproate versus intravaginal progesterone in IVF–embryo transfer cycles: a prospective randomized study

By Unfer Vittorio   Casini Maria Luisa   Costabile Loredana   Gerli Sandro   Baldini Domenico   Di Renzo Gc  

Reproductive BioMedicine Online, Vol. 9, Iss. 1, 2004-07 ,pp. : 17-21

Reproductive Healthcare Ltd

Access to resources Recommend Favorite